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1. Introduction 
World Health Organisation (WHO) type II anovulation is defined as normogonadotrophic 
normoestrogenic anovulation and occurs in approximately 85% of anovulatory patients. 
Polycystic ovary syndrome (PCOS) is the most common form of WHO type II anovulatory 
infertility and is associated with hyperandrogenemia (1,2). Moreover, PCOS is the most 
common endocrine abnormality in reproductive age women. The prevalence of PCOS is 
traditionally estimated at 4% to 8% from studies performed in Greece, Spain and the USA 
(3-6). The prevalence of PCOS has increased with the use of different diagnostic criteria and 
has recently been shown to be 11.9 ± 2.4% -17.8 ± 2.8 in the first community-based 
prevalence study based on the current Rotterdam diagnostic criteria compared with 10.2 ± 
2.2% -12.0 ± 2.4% and 8.7 ± 2.0% using National Institutes of Health criteria and Androgen 
Excess Society recommendations respectively (7). Importantly, 70% of women in this recent 
study were undiagnosed (7).  
Clomiphene citrate (CC) is still holding its place as the first-line therapy for ovulation 
induction in these patients (2,8,9). CC contains an unequal mixture of two isomers as their 
citrate salts, enclomiphene and zuclomiphene. Zuclomiphene is much the more potent of the 
two for induction of ovulation, accounts for 38% of the total drug content of one tablet and 
has a much longer half-life than enclomiphene, being detectable in plasma 1 month 
following its administration (10). CC is capable of inducing a discharge of FSH from the 
anterior pituitary and this is often enough to reset the cycle of events leading to ovulation 
into motion. This is achieved indirectly, through the action of CC, a non-steroidal compound 
closely resembling an estrogen, in blocking hypothalamic estrogen receptors, signalling a 
lack of circulating estrogen to the hypothalamus and inducing a change in the pattern of 
pulsatile release of GnRH(10). Standard practice is to administer CC for 5 days from the 
second or third day of the menstrual cycle, starting with 50mg/day and increasing to 
250mg/day (10). However managed care studies have shown that the most effective dosage 
is 100–150mg/day and over 75% of ovulations occur within these dosages (11). After six to 
nine cycles of treatment with CC cumulative pregnancy rates reach 70–75% (11). Life table 
analysis of the most reliable studies indicated a conception rate up to 22% per cycle in 
women ovulating on CC (8). In a large randomized trial, Legro et al., 2007 (12) compared the 
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effects of CC, metformin and combination therapy in 626 infertile women with PCOS. They 
reported an ovulation and clinical pregnancy rates per woman of 75.1% and 23.9% 
respectively, after CC treatment up to 150mg/day. 
Clomiphene resistance defined as failure to ovulate after receiving 150 mg of CC daily for 5 
days per cycle, for at least three cycles, is common and occurs in approximately 15 to 40% in 
women with PCOS (2, 13). Insulin resistance, hyperandrogenemia, and obesity represent the 
major factors involved in CC resistance; avert the ovaries from responding to raised 
endogenous FSH levels following CC therapy (14-16). Moreover, a genetic predisposition 
was suggested (17). 
The purpose of this chapter is to review the evidence based treatment strategies for 
ovulation induction in anovulatory PCOS patients with known CC resistance, both the 
traditional and new ones. The traditional options include gonadotrophins and surgery 
(laparoscopic ovarian drilling). New strategies as insulin-sensitizing drugs, aromatase 
Inhibitors, oral contraceptives, dexamethasone, N-acetyl-cysteine…etc. Moreover, 
optimizing the body mass index (BMI) firstly before commencing therapy is an important 
issue to improve the treatment outcome in obese anovulatory women with PCOS. In vitro 
fertilization (IVF) is the recommended line of treatment after failure of these strategies; 
however, it is outside the scope of this chapter. Finally an algorithm will be provided to 
facilitate management of this important clinical issue. 
2. Weight loss and lifestyle modifications 
Obesity is strongly associated with PCOS and may be present in up to 50% of cases (18-22). 
Obese women with PCOS are more likely than thin women with PCOS to suffer from 
anovulation (18). This effect on ovulation may be secondary to insulin resistance, which in 
turn results in hyperinsulinemia and stimulation of excess androgen production from the 
ovaries (22). Lifestyle modification is the first line treatment in an evidence based approach 
for the management of the majority of PCOS women who are overweight (8,9,13, 23-25). The 
NICE, 2004 (13) recommended weight loss for anovulatory PCOS women who have a BMI > 
29 kg/m2 before starting ovulation induction therapy. In these women, weight loss of even 
5% to 10% of body weight often restores ovulatory cycles (9, 19, 21). Studies also showed 
that overweight women are less likely to respond to pharmacologic ovulation induction 
methods. In a cohort of 270 women, with PCOS who received either CC or gonadotrophins 
for ovulation induction, almost 80% with a BMI of 18–24 kg/m2 ovulated at 6 months 
compared with only 12% of women with a BMI≥35 kg/m2 (18). Moreover, overweight 
women require higher doses of CC and gonadotrophins (19). 
The current recommendation is to reduce weight gradually to increase the chances of 
maintaining the weight loss (9). Preferential diet composition has been evaluated in 2 small 
studies (26, 27). These studies compared a high carbohydrate (55%), low protein (15%) 
hypocaloric diet with a low carbohydrate (40%), high protein (30%) hypocaloric diet and 
found similar weight loss and decrease in circulating androgen and insulin levels. Routine 
exercise is also very important in the reproductive health of PCOS women. Exercise 
increases insulin sensitivity and helps achieve and maintain weight loss (9, 25). 
Incorporating simple moderate physical activity including structured exercise (at least 30 
min/ day) and incidental exercise increases weight loss and improves clinical outcomes in 
PCOS, compared to diet alone (28). Also, a recent study reported that a 6-week intervention 
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of structured exercise training and a hypocaloric diet was effective in increasing the 
probability of ovulation under CC treatment in overweight and obese CC-resistant PCOS 
patients (29). Other lifestyle factors such as excessive caffeine intake, alcohol consumption, 
and smoking should also be addressed (13,20). 
Otta et al., 2010 (30) in a randomized, double-blind, and placebo control trial compared 
lifestyle modification and 1500 mg of metformin or placebo for 4 months in 30 women with 
insulin resistance PCOS. They reported that metformin has an additive effect to diet and 
exercise to improve parameters of hyperandrogenism and insulin resistance. However, a 
small decrease in body weight through lifestyle changes could be enough to improve 
menstrual cycles in these women. Karimzadeh & Javedani, 2010 (31)in another randomized 
double-blind study compared lifestyle modification with medical treatment plans such as 
CC, metformin, and CC with metformin in 343 overweight infertile women with PCOS. 
They showed that metformin or metformin with CC does not cause a significant weight loss 
or an improvement in the endocrine status of PCOS women. However, lifestyle modification 
to reduce waist circumference and body weight could improve their menstrual cycles, 
hormonal status and was an effective treatment for ovulation induction in those patients 
with an ovulation and pregnancy rates of 66.6% and 20% respectively. 
In morbidly obese women, the PCOS phenotype appears to be very frequent (32). 
Importantly, this disorder has been found to improve markedly after sustained weight loss 
following bariatric surgery (33). Anti-obesity pharmacological agents have been used in 
obese women with PCOS. Both orlistat, which blocks intestinal absorption of fat (34), and 
sibutramine, an appetite suppressant (35), have displayed a weight loss-independent effect 
on androgens and insulin resistance. It should be noted that these treatments should not be 
considered as first-line therapy for obesity in women with PCOS (8). 
3. Gonadotrophins 
Ovulation induction for women with anovulatory PCOS using gonadotrophin therapy is 
based on the physiological concept that initiation and maintenance of follicle growth may be 
achieved by a transient increase in FSH above a threshold dose for sufficient duration to 
generate a limited number of developing follicles (8). Traditionally, Ovulation induction 
with gonadotrophins has been used as a second line treatment for CC-resistant PCOS 
women, however it is expensive, requires extensive monitoring and associated with 
significantly increased risk for ovarian hyperstimulation syndrome (OHSS) and multiple 
pregnancy (8, 9, 13, 36-38). Furthermore, a significant and consistent relationship between 
PCOS and OHSS was reported in a systematic review (39). The high sensitivity of the PCOS 
to gonadotrophic stimulation is probably related to the fact that they contain twice the 
number of available follicle-stimulating hormone (FSH)-sensitive antral follicles in their 
cohort than the normal ovary (40). A meta-analysis concluded that the outcomes of 
treatment achieved with hMG and with FSH alone in infertile patients with PCOS were 
similar except for a reduction in the risk of OHSS with the urinary FSH (uFSH) (41). A low-
dose, step-up gonadotrophin therapy should be preferred to the now outdated conventional 
protocol for patients with PCOS and the strong justification seems to be; the achievement of 
high rate of mono-follicular development which is ~69% (54–88%) (36,42) with nearly 
complete elimination of OHSS (0–2.4%) and a multiple pregnancy rate of ~6% (36,43). The 
recommended approach is to begin with a low dose of gonadotrophin, typically 37.5– 75 
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IU/day, increasing after 7 days or more if no follicle >10 mm has yet emerged, in small 
increments, at intervals, until evidence of progressive follicular development is observed. 
The maximum required daily dose of FSH/hMG seldom exceeds 225 IU/day (38, 44). There 
is no evidence of a difference between recombinant FSH (rFSH) and uFSH for ovulation 
induction in CC- resistant PCOS women (45,46). In addition, a randomised trial (RCT) of 
highly purified uFSH (HP-uFSH) versus rFSH found that the former was non-inferior 
compared with the latter with respect to ovulation rate (85.2% versus 90.9%) in anovulatory 
WHO Group II women who failed to ovulate or conceive on CC (47) . 
4. Laparoscopic Ovarian Diathermy (LOD) 
Laparoscopic ovarian diathermy (LOD) is currently accepted as a successful second line 
treatment for ovulation induction in CC-resistant PCOS being as effective as gonadotrophin 
treatment and is not associated with an increased risk of multiple pregnancy or OHSS (8, 
9,13, 48-51). Bayram et al., 2004 (50) in a RCT compared LOD with rFSH in 168 CC-resistant 
PCOS women. They reported an ovulation rate of 70% and 69% per cycle and pregnancy 
and live-birth rates 37%, 75% and 34%, 60% of patients respectively following LOD and FSH 
therapy. In patients remaining anovulatory 8 weeks after LOD or those who subsequently 
became anovulatory, adjuvant therapy with CC or gonadotrophins was required to achieve 
equivalent pregnancy and live-birth rates (50). A Cochrane review found no difference in 
the rates of miscarriage, ongoing pregnancy or live birth between LOD and gonadotrophins. 
Multiple pregnancy rates were significantly lower with LOD than with gonadotrophins (1% 
versus 16%; OR 0.13, 95% CI 0.03 to 0.52) (49). A recent study concluded that LOD for 
women with CC-resistant PCOS is as effective as ovulation induction with rFSH treatment 
in terms of live births, but reduces the need for ovulation induction or ART in a significantly 
higher proportion of women and increases the chance for a second child (52). 
The main shortcomings of LOD are the need for general anesthesia and the risk of 
postoperative adhesions (53, 54). The claim that it might affect the ovarian reserve is not 
more than a theoretical concern since a recent report concluded that LOD, when applied 
properly, does not seem to compromise the ovarian reserve in PCOS women (55). Moreover, 
an economic evaluation has shown that the cost of a live birth after LOD is approximately 
one-third lower than the equivalent cost of gonadotrophin treatment (56). The most 
commonly used energy for LOD is electrocautery. It has been reported that the clinical and 
endocrine response to LOD is governed by a dose response relationship. Four punctures per 
ovary using a power setting of 30 W applied for 5s per puncture (i.e. 600 J per ovary) are 
sufficient to produce an optimal response (67% spontaneous ovulation rate and 67% 
conception rate). Reducing the thermal energy below that level reduces the chances of 
spontaneous ovulation and conception (57). Also, different studies argued for unilateral 
LOD being equally efficacious as bilateral drilling in inducing ovulation and achieving 
pregnancy in CC resistant PCOS patients and may be regarded as a suitable option with the 
potential advantage of decreasing the chances of adhesion formation (58-60). 
Although it remains unclear as to how LOD induces ovulation, a potential mechanism is 
that LOD drains the ovarian follicles containing a high concentration of androgens and 
inhibin, which causes the reduction of blood androgens and blood inhibin resulting in an 
increase of FSH and recovery of the ovulation function (51,53, 61,62). Surgery may also 
provoke an increased blood flow to the ovary, allowing increased delivery of 
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gonadotrophins (53, 62). Women with marked obesity (BMI >35 kg/m2), marked 
hyperandrogenism (serum testosterone concentration >4.5 nmol/l, free androgen index 
(FAI) >15) and/or long duration of infertility (>3 years) seem to be poor responders to LOD. 
On the other hand, high LH levels >10 IU/l in LOD responders appear to predict higher 
probability of pregnancy (63). van Wely et al., 2005 (64) reported that women who had an 
age at menarche < 13years, an LH/FSH ratio < 2 and a glucose level < 4.5 mmol/l, were 
more likely to remain anovulatory following LOD. 
Restoration of consecutive spontaneous ovulations after LOD in some CC-resistant PCOS 
patients is one of the most important advantages of this approach (65). Another potential 
advantage is the increased responsiveness of the ovary to oral ovulation induction agents 
following the procedure. In a recent study, we evaluated whether LOD in CC-resistant 
PCOS patients led to the restoration of CC-sensitivity. LOD was performed in 234 CC-
resistant PCOS patients. In 150 patients ovulation occurred. The remaining 84 aonvulatory 
patients were again treated with CC. Ovulation occurred in 30 /84 patients (35.7%), 
meanwhile, pregnancy occurred in 13/ 84 patients (15.5%). Hyperandrogenism and insulin 
resistance were negative predictors (66). 
5. Insulin-sensitizing drugs 
Approximately 50%-70% of all women with PCOS have some degree of insulin resistance 
(67). Hyperinsulinemia probably contributes to the hyperandrogenism which is responsible 
for the signs and symptoms of PCOS (67). Metformin, a biguanide, is now the most widely 
insulin sensitizer used for ovulation induction in women with PCOS. In these women, it 
appears to affect ovarian function in a dual mode, through the alleviation of insulin excess 
acting upon the ovary and through direct ovarian effects. Being an insulin sensitizer, it 
reduces insulin secretion and, consequently, lowers circulating total and free androgen 
levels with a resulting improvement of the clinical sequelae of hyperandrogenism. 
Importantly, it also seems to have a direct action on ovarian theca cells to decrease androgen 
production (68). A recent meta-analysis of RCTs showd no significant difference in 
effectiveness of metformin versus CC as a first-line treatment for ovulation induction in 
non-obese women with anovulatory PCOS (69). Also a recent Cochrane review reported that 
metformin is still of benefit in improving clinical pregnancy and ovulation rates. However, 
there is no evidence that it improves live birth rates whether it is used alone or in 
combination with CC, or when compared with CC. Therefore, the use of metformin as a 
first-line treatment in improving reproductive outcomes in women with PCOS appears to be 
limited (70). 
Many investigators have demonstrated an improvement in insulin sensitivity and a 
significant decrease in serum insulin and free testosterone levels after long term treatment 
with metformin for 5–8 weeks (71-73). Creanga et al., 2008 (74) in a meta-analysis, confirmed 
that metformin in combination with CC increased the likelihood of ovulation [OR 4.39, 95% 
CI 1.94–9.96, number - needed- to-treat (NNT) 3.7] and pregnancy (OR 2.67, 95% CI 1.45–
4.94, NNT 4.6) in comparison with CC alone, especially in CC-resistant and obese PCOS 
patients. Actually, different mechanisms explaining why metformin therapy would facilitate 
ovulation induction by CC in CC- resistant PCOS patients have been proposed entailing; an 
intrinsic alteration of follicle steroidogenesis through the IGF-I pathway in granulosa cells 
(73); direct inhibition of androgen production in ovarian thecal cells (75); reduction in the 
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adrenal steroidogenesis response to ACTH (76) and recently its central action on the 
pituitary gland with an LH lowering and prolactin effects in the PCOS women (77). There 
are unpleasant gastrointestinal side effects including nausea, vomiting, bloating, cramps and 
diarrhoea. Rare complication includes lactic acidosis. Metformin has been used in increasing 
doses from 500 to 1500 mg daily for the induction of ovulation in women with PCOS (9).  
Recently, the efficacy of the combination of metformin and CC versus other traditional 
options including gonadotrophins and LOD for treatment of CC-resistant infertile PCOS 
patients has been reported. Two RCTs compared the combination of metformin and CC 
with LOD, showing that both are effective approaches to treat CC- resistant infertile PCOS 
patients (78, 79). In fifty primary infertile patients with CC- resistant PCOS, Palombo et al., 
2010 (78) found no significant difference between the 2 groups in pregnancy and live-birth 
rates per cycle (13.1% vs.16.3% and 11.2% vs. 14.1% respectively). However, the ovulation 
rate per cycle was significantly lower in LOD group than in Metformin/CC group (56.5% vs. 
72.0%). On the other hand, in a well designed adequately powered RCT comprised of 282 
anovulatory women with CC-resistant PCOS, we reported no significant difference between 
the 2 groups in ovulation and pregnancy rates per cycle (67% vs. 68.2% and 15.4% vs. 17% 
respectively). However, a significant difference regarding midcycle endometrial thickness 
was found (9.2 ± 1.2 mm vs. 7.6 ± 1.1 mm, in Metformin/CC and LOD groups respectively) 
(79). George et al., 2003 (80) in a small trial of limited power compared sequential treatment 
of metformin and CC with conventional hMG protocol in 60 CC-resistant PCOS patients. In 
this trial, metformin alone was given as a single pretreatment for 6 months, followed by 
ovulation induction with CC. There was no significant difference in pregnancy rates 
between the two groups (16.7 vs. 23.3%). However, in the metformin group, significant 
improvements in menstrual function and ovulation rate of 46.7% with a significant decrease 
in fasting insulin levels were reported. The ovulation rate in hMG group was 43.3%, with a 
high drop-out rate. Recently, in a well designed adequately powered RCT we compared the 
effects of combined metformin–CC with HP-uFSH using low-dose, step-up regimen for 
three cycles in 153 anovulatory women with CC-resistant PCOS (81). Actually, combined 
metformin-CC therapy was not expected to be more effective than gonadotrophins, 
however, it did result in modest ovulation and pregnancy rates. Ovulation and pregnancy 
rates per cycle were 62% vs. 83.8% and 11.2% vs. 21.5% in combined metformin- CC group 
and HP-uFSH groups respectively. HP-uFSH administration had good results, but, the low-
dose, step-up regimen requires extensive monitoring and expertise, and has high costs. 
Accordingly, it is logical to offer combined metformin- CC therapy first in the step-wise 
treatment protocol for CC-resistant PCOS patients before resorting to more expensive 
alternatives especially in developing communities where economic aspects of therapy are 
important (81). 
The safety of metformin has sparked a heated debate. Recent evidence that metformin is 
probably safe during the first trimester of pregnancy and beyond is accumulating (82-85). 
Moreover, a recent meta-analysis found no effect of pregestational metformin 
administration on abortion risk in PCOS patients (86). Other insulin sensitizers from the 
thiazolidenediones family, namely rosiglitazone, have been used effectively in CC-resistant 
PCOS patients. In a RCT, the combination of rosiglitazone and CC was reported to be more 
effective than metformin and CC in terms of ovulation rate (64.3 vs. 36.4%, respectively); 
whereas no statistical significance was observed in pregnancy rate (50 vs. 38.5%) (87). Also, 
a recent RCT reported no significant difference between combined treatment with 
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rosiglitazone and CC vs. LOD in 43 CC-resistant PCOS patients in terms of biochemical 
response, ovulation rate (80.8 vs. 81.5%) and pregnancy rate (50 vs. 42.8%) (88). A 
retrospective analysis investigated various clinical, biochemical, and ultrasonographic 
factors that determine clinical response to rosiglitazone as a first-line therapy in a series of 
PCOS women with newly diagnosed CC-resistance. It showed that marked obesity, marked 
hyperandrogenism, and long duration of infertility were predictors of resistance to 
rosiglitazone therapy (89). 
6. Third-generation aromatase inhibitors 
Third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) are approved 
adjuvants for treatment of estrogen-receptor–positive breast cancer (90) that were first used 
in ovulation induction in anovulatory women in 2001 (91). Evidence suggests that 
nonsteroidal aromatase inhibitors (AIs), specifically letrozole and anastrozole, have 
ovulation-inducing effects by inhibiting androgen-to-estrogen conversion. Centrally, this 
effect releases the hypothalamic/pituitary axis from estrogenic negative feedback, increases 
gonadotrophin secretion, and results in stimulation of ovarian follicle maturity. Moreover, 
peripherally, AIs may increase follicular sensitivity to FSH (92). AIs have relatively short 
half-lives (~2 days) compared with CC (~2 weeks) so estrogen target tissues (e.g., 
endometrium and cervix ) are spared adverse effects. Because of these mechanisms, it was 
postulated that AIs may have superior ovulation induction properties in terms of follicular 
growth and endometrium development, which is important for embryo implantation (92). 
Recent studies showed that letrozole has better ovulation and pregnancy rates in 
comparison to CC and placebo in patients with CC- resistant PCOS (93-96). There are 2 
prospective studies in the literature comparing the two commercially available third 
generation AIs, letrozole and anastrozole in CC-resistant infertile women with PCOS. Al-
Omari et al., 2004 (97) studied 40 cases who were considered CC- resistant if failed ovulation 
after 200 mg CC daily for 5 days or were ovulatory with an endometrium thickness less than 
5 mm. Ovulation and pregnancy rates per cycle were significantly higher with letrozole 
compared with anastrozole (84.4% vs. 60% and 18.8% vs. 9.7%, respectively). Endometrium 
thickness was significantly greater for letrozole compared with anastrozole (8.16 ± 1.32 vs. 
6.53 ± 1.55 mm). Multiple pregnancies did not occur. In this small trial, PCOS diagnostic 
criteria were not stated. Additionally, the dose of CC used to define resistance was very 
high, possibly suggesting an extremely refractory population. Importantly, a larger RCT 
compared the efficacy of letrozole and anastrozole in 220 CC–resistant women with PCOS 
diagnosed with Rotterdam criteria. More growing and mature follicles and greater 
endometrial thickness in patients receiving anastrozole were demonstrated; however, no 
significant advantage for anastrozole over letrozole with regard to ovulation, pregnancy or 
miscarriage rates was observed (63.4 vs.62% and 15.1vs. 12.2% and 9.5vs. 11.1% 
respectively). Two twin pregnancies occurred with letrozole, while none occurred with 
anastrozole (98). In the above mentioned 2 studies, a short course (5 days) of letrozole was 
used. However, a long letrozole protocol (10 days) was also proposed, with proved 
advantages in terms of more mature follicles and subsequently more pregnancies (99).  
One small trial of limited power compared combined metformin–letrozole vs. metformin–
CC in 60 CC-resistant PCOS patients reported that combined metformin–letrozole was 
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associated with significantly more endometrial thickness, E2 levels and full-term pregnancy 
rate. However, no statistically significant difference was found between the two groups as 
regards the mean number of mature follicles, ovulation and pregnancy rates. The authors 
admitted that combined metformin– letrozole is better than letrozole alone, particularly in 
overweight women and asked for further studies to confirm their hypothesis (100). Recently, 
in a well designed adequately powered RCT, we compared the effects of letrozole 
monotherapy (2.5 mg daily for 5 days from D3-7 of the cycle) with combined metformin–CC 
in 250 anovulatory women (582 cycles) with CC resistant PCOS. Our findings suggested that 
letrozole monotherapy and combined metformin-CC were equally effective for inducing 
ovulation and achieving pregnancy in patients with CC-resistant PCOS (64.9% vs.69.6% and 
14.7% vs. 14.4% respectively). The total number of follicles was significantly more in the 
combined metformin–CC group (4.4 ± 0.4 vs. 6.8 ± 0.3). A non significant increase in 
endometrial thickness on the day of hCG administration was observed in the letrozole 
group (9.5 ± 0.2 mm vs. 9.1 ± 0.1 mm). Since letrozole was well tolerated, it is considered as 
an acceptable alternative if CC-resistant PCOS patients cannot tolerate long-term metformin 
pretreatment (101).  
More recently, the efficacy of the AIs vs. other traditional options including gonadotrophins 
and LOD for treatment of CC-resistant infertile PCOS patients has been reported. 2 RCTs 
compared the effect of letrozole (2.5mg and 5 mg respectively from day 3 to day 7 of menses 
for 6 consecutive cycles) with LOD for ovulation induction in CC resistant women with 
PCOS. Both trials reported that letrozole and LOD are equally effective for inducing 
ovulation and achieving pregnancy in these patients. Moreover, women in the letrozole 
group had a significantly thicker endometrium than those in the LOD group. In view of the 
invasiveness and cost of surgery, it seems plausible that letrozole therapy should be tried 
first for most of those women before shifting to LOD (102,103). A recent large randomized 
trial by Ganesh et al., 2009 (104) compared the efficacy of letrozole with that of rFSH and 
CC/rFSH for ovarian stimulation in IUI cycles in 1387 PCOS women after CC failure. They 
reported an ovulation rate of 79.30% in letrozole group vs. 56.95% and 89.89% in other 
groups respectively and pregnancy rate of 23.39% in letrozole group vs. 14.35% and 17.92% 
in other groups respectively. However, they included not only CC-resistant PCOS patients 
but also those who failed to conceive with100 mg/day CC for 6 cycles despite ovulating and 
those who showed poor endometrial development i.e. endometrial thickness < 7 mm on the 
day of hCG administration. 
Letrozole was evaluated in 44 women with CC–resistant PCOS and both responders and 
nonresponders were characterized. PCOS was diagnosed by Rotterdam criteria; CC- 
resistance was defined as failure to ovulate after 6 cycles of 150 mg CC /day for 5 days. 
Whereas response to CC is less likely with elevated BMI, amenorrhea, and increased age, 
significant differences between letrozole responders and nonresponders were not noted for 
any evaluated measure. This apparent lack of predictive factors for letrozole suggests utility 
in CC–resistant patients since its efficacy is not limited to specific patient characteristics 
(105). The safety of letrozole has elaborated a vivid discussion. Preliminary data by Biljan et 
al., 2005 (106) suggested an increased risk of congenital anomalies in letrozole treated 
babies, whereas recent data from retrospective and prospective trials (107,108) have 
contested these initial findings and supported the safety of letrozole compared to traditional 
ovulation induction treatment. 
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7. Oral contraceptives 
Branigan & Estes., 2003 (109) in a RCT showed that the suppression of the hypothalamic 
pituitary- ovarian axis for 2 months with combined oral contraceptives (COC) (0.03 mg of 
ethinyl estradiol and 0.15 mg of desogestrel) followed by CC, at dosage of 100 mg/day on 
days fifth to ninth of the cycle, improved ovulation and pregnancy rates in CC resistant 
women in comparison with repeated cycles of CC alone. Oral contraceptive administration 
showed to reduce serum LH, estradiol and androgen levels. These hormonal changes, 
especially the reduced androgenic milieu, could act improving the ovarian 
microenvironment, and thus the ovarian response to CC. Kriplani et al., 2010 (110) in a RCT 
reported that in women with PCOS, a drospirenone containing COC has better outcome in 
terms of persistent regular cycles, antiandrogenic effect,fall in BMI and BP, better lipid 
profile, favorable glycemic and hormonal profile than desogestrel-containing COC. 
8. N-acetyl-cysteine 
N-acetyl-cysteine (NAC) is a mucolytic drug. Fulghesu et al., 2002 (111) demonstrated that 
long term NAC treatment (1.8 g/d for 5–6 weeks) was associated with significant increase in 
insulin sensitivity and reduction in insulin levels, testosterone and FAI in hyperinsulinemic 
PCOS. Rizk et al., 2005 (112) showed that the combination of NAC (1.2 g/d) with CC (100 
mg/d) for only 5 days significantly increased both ovulation and pregnancy rates in obese 
women with CC-resistant PCOS compared with placebo (49.3% vs. 1.3% and 21.3% vs. 0, 
respectively). Actually, these results supporting the shorter duration (5 days only) of NAC 
administration in CC- resistant PCOS women have not been replicated by other trials. 
Recently, in a well designed adequately powered RCT, we reported that the efficacy of 
metformin–CC combination therapy is higher than that of NAC – CC for inducing ovulation 
and achieving pregnancy among CC-resistant PCOS patients (113). In our study, the dose 
and duration of NAC were chosen based on that published by Fulghesu et al., 2002(111). 
Over a 3-month follow-up period, women in metformin-CC group had significantly higher 
ovulation and pregnancy rates compared with women in NAC-CC group (69.1% vs. 20.0% 
and 22.7% vs. 5.3%, respectively). Moreover, the level of serum estrogen, the endometrial 
thickness on the day of hCG administration and the midluteal serum progesterone level 
were all significantly higher for women in metformin-CC group than other group. 
Additionally, a lower miscarriage rate was observed among women in metformin-CC group 
(113). 
9. Dexamethasone therapy 
Dexamethasone therapy during the follicular phase has been described without any side 
effects or serious events (114). Parsanezhad et al., 2002 (115) in a double-blind RCT, showed 
the safety and the efficacy of a high-dose short course of dexamethasone for inducing 
ovulation in 230 CC-resistant patients with PCOS and normal DHEAS levels. They reported 
significantly higher ovulation and pregnancy rates in those who received 200mg of CC 
(days 5–9) and 2mg of dexamethasone (days 5–14) compared with CC alone (88% vs. 20% 
and 40.5 vs. 4.2% respectively). In these patients, dexamethasone reduced circulating 
DHEAS, T, and LH levels and the LH/FSH ratio after 2 weeks of treatment (115). These 
results were further confirmed in another RCT (116).  
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Currently, evidence suggests that PCOS and hyperprolactinaemia are two distinct entities 
without a patho-physiological link (117-119). Bromocriptine administration provided no 
benefit in CC-resistant PCOS patients with normal prolactin levels, receiving 150mg CC 
(days 5–9) and bromocriptin continuously administrated at a dosage of 7.5 mg daily (120). 
On the contrary, the use of cabergoline, a long-acting ergoline D2 agonist derivative, has 
been proved to improve ovarian response in hyperprolactinemic patients with PCOS 
candidates for treatment with gonadaotrophins (121). These data suggested the presence of 
a dopaminergic component in the control of LH release in PCOS patients (121). 
11. Conclusion 
Ovulation induction in women with PCOS who present with CC-resistant anovulatory 
infertility remains a major challenge in gynecologic endocrinology. Traditional alternatives 
for CC-resistant patients include gonadotrophin therapy and laparoscopic ovarian 
diathermy. However, because of the cost and risk inherent in these therapies, alternative 
treatments are attractive. Obese PCOS women should try to attain BMI<30kg/m2 prior to 
commencing ovulation induction therapy. In view of our experience, combined metformin-
CC therapy did result in modest ovulation and pregnancy rates. Accordingly, it is logical to 
offer combined metformin- CC therapy for CC-resistant PCOS patients before resorting to 
more expensive alternatives especially in developing communities where economic aspects 
of therapy are important. Third generation aromatase inhibitors are promising agents for 
treatment in these patients. Figure 1 shows an algorithm for ovulation induction treatment 
in anovulatory infertile women with CC-resistant PCOS. 
CC- resistant PCOS
Optimize lifestyle
= Weight loss (Diet + exercise)
if BMI >29 Kg/m2
 Metformin+ CC (3-6 cycles)
 3rd generation AIs (Letrozole




Obese women Non Obese women
FailureCC: Clomiphene Citrate
AIs: Aromatase inhibitors
LOD: laparoscopic ovarian drilling
 
Fig. 1. Algorithm for ovulation induction treatment in anovulatory infertile women with 
CC-resistant PCOS. 
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